217 related articles for article (PubMed ID: 31409888)
21. Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.
Palechor-Ceron N; Krawczyk E; Dakic A; Simic V; Yuan H; Blancato J; Wang W; Hubbard F; Zheng YL; Dan H; Strome S; Cullen K; Davidson B; Deeken JF; Choudhury S; Ahn PH; Agarwal S; Zhou X; Schlegel R; Furth PA; Pan CX; Liu X
Cells; 2019 Oct; 8(11):. PubMed ID: 31717887
[TBL] [Abstract][Full Text] [Related]
22. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.
Pelizzo G; Veschi V; Mantelli M; Croce S; Di Benedetto V; D'Angelo P; Maltese A; Catenacci L; Apuzzo T; Scavo E; Moretta A; Todaro M; Stassi G; Avanzini MA; Calcaterra V
BMC Cancer; 2018 Nov; 18(1):1176. PubMed ID: 30482160
[TBL] [Abstract][Full Text] [Related]
23. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
24. N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.
Feduska JM; Garcia PL; Brennan SB; Bu S; Council LN; Yoon KJ
BMC Cancer; 2013 May; 13():261. PubMed ID: 23714211
[TBL] [Abstract][Full Text] [Related]
25. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.
Pieraccioli M; Nicolai S; Pitolli C; Agostini M; Antonov A; Malewicz M; Knight RA; Raschellà G; Melino G
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):7356-7361. PubMed ID: 29941555
[TBL] [Abstract][Full Text] [Related]
26. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
27. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
29. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor effect of sulfasalazine in neuroblastoma.
Mooney MR; Geerts D; Kort EJ; Bachmann AS
Biochem Pharmacol; 2019 Apr; 162():237-249. PubMed ID: 30639262
[TBL] [Abstract][Full Text] [Related]
31. Generation and characterization of novel local and metastatic human neuroblastoma variants.
Nevo I; Sagi-Assif O; Edry Botzer L; Amar D; Maman S; Kariv N; Leider-Trejo LE; Savelyeva L; Schwab M; Yron I; Witz IP
Neoplasia; 2008 Aug; 10(8):816-27. PubMed ID: 18683320
[TBL] [Abstract][Full Text] [Related]
32. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.
Capasso M; Brignole C; Lasorsa VA; Bensa V; Cantalupo S; Sebastiani E; Quattrone A; Ciampi E; Avitabile M; Sementa AR; Mazzocco K; Cafferata B; Gaggero G; Vellone VG; Cilli M; Calarco E; Giusto E; Perri P; Aveic S; Fruci D; Tondo A; Luksch R; Mura R; Rabusin M; De Leonardis F; Cellini M; Coccia P; Iolascon A; Corrias MV; Conte M; Garaventa A; Amoroso L; Ponzoni M; Pastorino F
J Transl Med; 2024 Feb; 22(1):151. PubMed ID: 38351008
[TBL] [Abstract][Full Text] [Related]
33. A new tumorsphere culture condition restores potentials of self-renewal and metastasis of primary neuroblastoma in a mouse neuroblastoma model.
Cao D; Kishida S; Huang P; Mu P; Tsubota S; Mizuno M; Kadomatsu K
PLoS One; 2014; 9(1):e86813. PubMed ID: 24466252
[TBL] [Abstract][Full Text] [Related]
34. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
Alam G; Cui H; Shi H; Yang L; Ding J; Mao L; Maltese WA; Ding HF
Am J Pathol; 2009 Aug; 175(2):856-66. PubMed ID: 19608868
[TBL] [Abstract][Full Text] [Related]
35. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
36. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
[TBL] [Abstract][Full Text] [Related]
37. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a neuroblastoma mouse model by subcutaneous xenograft transplantation and its use to study metastatic neuroblastoma.
Gao Q; Chen CF; Dong Q; Hou L; Chen X; Zhi YL; Li X; Lu HT; Zhang HY
Genet Mol Res; 2015 Dec; 14(4):16297-307. PubMed ID: 26662423
[TBL] [Abstract][Full Text] [Related]
39. Study of the phenotypic relationship in the IMR-32 human neuroblastoma cell line by sedimentation field flow fractionation.
Bégaud-Grimaud G; Battu S; Lazcoz P; Castresana JS; Jauberteau MO; Cardot PJ
Int J Oncol; 2007 Oct; 31(4):883-92. PubMed ID: 17786321
[TBL] [Abstract][Full Text] [Related]
40. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
